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Background: The success of cancer hyperthermia (HT) treatments is strongly dependent on the tem-
peratures achieved in the tumor and healthy tissues as it correlates with treatment efficacy and safety,
respectively. Hyperthermia treatment planning (HTP) simulations have become pivotal for treatment
optimization due to the possibility for pretreatment planning, optimization and decision making, as
well as real-time treatment guidance.
Materials and methods: The same computational methods deployed in HTP are also used for in silico
studies. These are of great relevance for the development of new HT devices and treatment
approaches. To aid this work, 3 D patient models have been recently developed and made available
for the HT community. Unfortunately, there is no consensus regarding tissue properties, simulation set-
tings, and benchmark applicators, which significantly influence the clinical relevance of computa-
tional outcomes.
Results and discussion: Herein, we propose a comprehensive set of applicator benchmarks, efficacy
and safety optimization algorithms, simulation settings and clinical parameters, to establish bench-
marks for method comparison and code verification, to provide guidance, and in view of the 2021
ESHO Grand Challenge (Details on the ESHO grand challenge on HTP will be provided at https://www.
esho.info/).
Conclusion: We aim to establish guidelines to promote standardization within the hyperthermia com-
munity such that novel approaches can quickly prove their benefit as quickly as possible in clinically
relevant simulation scenarios. This paper is primarily focused on radiofrequency and microwave hyper-
thermia but, since 3 D simulation studies on heating with ultrasound are now a reality, guidance as
well as a benchmark for ultrasound-based hyperthermia are also included.
Abbreviations: CTV: Clinical target volume; ESHO: European Society for Hyperthermic Oncology; GTV:
Gross tumor volume; HTV: Hyperthermia target volume; H&N: Head and neck; HT: Hyperthermia; HTP:
Hyperthermia treatment planning; SAR: Specific absorption rate; T: Temperature; THQ: Target hot spot
quotient; TC: Target coverage; TC25: volume percentage of the HTV covered by the 25% iso-SAR con-
tour; TC50: volume percentage of the HTV covered by the 50% iso-SAR contour; TC75: volume per-
centage of the HTV covered by the 75% iso-SAR contour; T10: temperatures achieved in at least 10%
of the HTV; T50: temperatures achieved in at least 50% of the HTV; T90: temperatures achieved in at
least 90% of the HTV; QA: Quality assurance.
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Hyperthermia therapy (HT), heating tumor tissue within
40–44 C, is an adjuvant cancer treatment that has shown to
be a potent sensitizer to radiotherapy and chemotherapy
[1,2]. HT is typically applied using radiofrequency (RF) or
microwave (MW) electromagnetic waves, but other modal-
ities, such as focused ultrasound (FUS), infrared, ferromag-
netic seeds, and magnetic nanoparticles, are also used for HT
delivery [3,4]. Although clinical results clearly favor the use of
adjuvant HT, the generally assumed optimum temperature of
43 C in the entire target region is usually not achieved in
clinical practice [5,6]. On the one hand, treatment with cur-
rent devices is associated with substantial unwanted heating
in normal tissues (hot spots), which prevents adjustment of
total power to induce the desired target temperature. Also,
the temperature in the target region is inhomogeneous due
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to region-specific, strongly variable and unknown tissue
properties [7]. On the other hand, current thermal dosimetry
during treatment is very limited, leading to an incomplete
picture of the heating patterns achieved. Hence, both
improvement of HT delivery techniques, as well as HT dosim-
etry, are warranted to bring HT to the twenty first century.
To address the aforementioned limitations, computational
modeling of RF/MW/FUS applicator designs and HT treat-
ment optimization play an important role [3,8–10]. However,
in contrast to the availability of simulation tools and compu-
tational power, our understanding of tissue properties and
the most suitable hyperthermia treatment planning (HTP)
techniques is only slowly increasing. The choices that have
to be made in simulations are often unclear and/or incom-
plete but strongly influence the absorbed power and tem-
perature predictions. In addition, the enhanced availability of
modeling tools and all their different numerical methods
have led to a situation in which comparison of the benefits
of the various computational modeling strategies is nearly
impossible. This lack of standardization limits further pro-
gress in the HT field, which motivated the European Society
of Hyperthermic Oncology (ESHO) to launch the ESHO Grand
Challenge 2021 on HT-based computational modeling,
including HTP, which is aimed at accelerating progress in
simulation-based HT technology (Appendix 1 and 2). Hereto,
we present guidelines and benchmarks for computational
modeling of HT applications designed to ensure uniformity
of in silico modeling and improve HTP quality.
HTP involves a two-step process: first, the specific absorp-
tion rate (SAR) in W/kg or Power Loss Density (PLD) in W/m3
is calculated, which is then integrated into the heat transfer
analysis to compute temperature (T). [The de facto unit
standard of temperature in HT clinical practice is degrees
centigrade (C), not the SI unit Kelvin (K).] HTP has a promin-
ent role in the guidance of clinical assessments, but the
same simulation techniques also provide a framework to
develop and optimize novel HT devices and treatment strat-
egies. The role of HTP in clinical guidance is multifold and
includes (1) the selection of applicator type and arrangement
[11–16], (2) analysis of the applicator heat-ability in nonstan-
dard clinical cases [11,12,17,18], (3) as the basis for interdis-
ciplinary discussions, and (4) investigation to what extent
potential contraindications compromise treatment. HTP is
also used during treatment for the (5) treatment adaptation
based on measurements or feedback from the patient
[19–21]. After treatment, HT-based computational modeling
helps in (6) retrospective analyses of the suitability of the
settings used during treatment. Another area where HTP
plays an important role is (7) the education and training of
hyperthermia technicians, physicists, and physicians. Besides
these seven treatment-related applications of HTP, it also has
a prominent role in the design and optimization of novel
devices and treatment strategies, and as part of closed-loop
control using rapid, model-guided, treatment adaptation
based on feedback during treatment administration.
Initially, HTP using computational modeling was mainly a
research tool and, therefore, not mentioned in any quality
assurance (QA) document in hyperthermia. Empirical steering
protocols were used, which are rather effective because of
the relatively large wavelengths associated with frequencies
used in the clinic (60–120MHz) and the relatively low num-
bers of antennas per applicator. However, significant pro-
gress in HTP, as described in several review papers [9,22,23],
increased clinical use, and the QA guidelines reported for the
first time by Bruggmoser et al. in 2012 recommend the rou-
tine use of HTP [24]. Clinical investigations showed that
treatment quality could indeed be ensured or improved by
the use of HTP [19–21,25]. In superficial and interstitial
hyperthermia QA guidelines, patient-specific HTP is now
mentioned as a tool to gain an understanding of the quality
of the applied heat distribution [26,27] like in cases that
deviate from typical treatment situations [11,12,17]. However,
while HTP is gaining traction, there is limited convergence
toward standard computational practices, tissue properties
and benchmark models. The exception relies on the IT’IS
Foundation tissue properties database that includes dielec-
tric, acoustic, thermal, perfusion, and other properties [28].
Besides being the most up-to-date tissue properties data-
base, it provides unambiguous traceability via a unique
Digital Object Identifiers (DOI).
The purpose of this paper is to define benchmarks for
computational modeling of HT studies using clinically-
derived patient models that can be utilized to assess the
potential clinical improvement offered by the various HT
technologies. These include new applicators or optimization
techniques. In this respect, a set of anatomical models for
studying the application of hyperthermia in the pelvis and
head and neck (H&N) areas was recently published and
made available to the general public [29]. Building on these
anatomical models, we added two breast cancer patient
models and further suggest consistent tissue properties and
simulation approaches, which allow comparison of the per-
formance of different devices, algorithms and treatment
approaches. Hereto, we describe open-source computational
anatomical models and simplified applicator models that
mimic those used in the clinic, as well as simulation settings,
quality metrics, and optimization goals (functionals). In this
paper, the focus is on RF/MW HT, but guidance on FUS is
also provided. Our intent is to use patient models as well as
applicator setups and procedures matching those accepted
in clinical practice. In summary, this paper serves to:
 provide benchmarks to verify the correctness of a treat-
ment modeling implementation and to support qual-
ity assurance;
 provide benchmarks to assess and compare the perform-
ance of treatment optimization approaches;
 provide guidance on computational treatment modeling,
as well as input for future standardization.
Finally, this paper is intended to serve as the basis for the
ESHO 2021 Grand-challenge on hyperthermia computational
modeling . This challenge aims at invigorating and streamlin-
ing progress in hyperthermia device development and treat-
ment strategy research, by providing standardized simulation
benchmarks to evaluate the predicted clinical improvement.
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In other words, it serves to provide the forum to display the
potential of new hyperthermia developments in a standar-
dized framework introduced in this paper. The new develop-
ments can include the comparison of different treatment
planning approaches, optimization strategies and applicators
for existing disease sites, as well as provide guidance for
novel applicators for novel sites. Further, in order to stimu-
late cross-modality comparisons, the challenge is open not
only for RF/MW but also US technologies. The details are
provided in Appendix 2 and at https://www.esho.info/
GrandChallenge, where registration for the ESHO grand chal-
lenge is possible.
2. Materials and methods
The following sections will cover all steps required to gener-
ate a computational model for a wide range of hyperthermia
applications. Most methods and recommendations have
been published elsewhere, but have not been compiled into
one cohesive guideline, a gap that we aim to address in the
following sections.
2.1. Patient models
In HTP simulation studies, cylindrical, homogeneous or
healthy-volunteer-based models are commonly used
[12,14,17,30–35]. However, these models lack the necessary
anatomical details, do not include the changes in patient
anatomy due to tumor growth and/or the patient/volunteer
posture is different from treatment position. Several studies
have shown the non-representative nature of such models
[12,14,17,35]. We recommend using realistic patient models
in hyperthermia modeling investigations and therefore pro-
pose a set of six patient models that cover some of the most
common hyperthermia treatment sites with these considera-
tions in mind.
Computer-aided design (CAD) models of four patients were
selected from the Erasmus Virtual Patient Repository (EVPR) [29]
and two newly developed breast patient models are considered
as the baseline for our benchmark studies (Figures 1–3). The
EVPR models are from patients referred for regular hyperther-
mia in the pelvic and H&N regions. For the pelvic region, we
selected two patients treated for cervical (Clarice) and rectal
cancer (Will), where the rectal tumor was significantly large and
thus more challenging to heat. Both H&N cases were challeng-
ing, which reflects the fact that hyperthermia in this region is
intrinsically complex, and many patients present heating com-
plications for different reasons. One of the patient models
presents a nasopharynx tumor (Alex) and the other is a postop-
erative case (Murphy) with no gross tumor volume (GTV) pre-
sent. For the breast models, we included one patient with a
superficial tumor (Venus) and another with a deep-seated
tumor (Luna). As in the clinical routine, models of patients with
H&N (Alex, Murphy) or breast (Venus, Luna) cancer have a
hyperthermia target volume (HTV) that comprises the GTV plus
a margin of 10mm, whereas for pelvic cancer patients models,
the HTV was the same as the GTV. More details on these EVPR
models can be found in [29].
2.2. Benchmark applicators
The proposed benchmark applicators were developed using
simplified versions of reference applicators (Table 1). A recent
publication by Paulides et al. [3] provides a comprehensive
review of commercial RF/MW applicators in clinical use for
the combination of chemotherapy with hyperthermia. From
the list of clinical applicators, we took inspiration from the
BSD Sigma family (Pyrexar, Salt Lake City UT, USA) [36,37],
and the HyperCollar (Erasmus MC, Rotterdam, the
Netherlands) [38–40] as well as HyperCollar3D (Sensius BV,
Rotterdam, The Netherlands) [11,41,42] applicators. Our selec-
tion was based on the large body of literature, the standard
application of HTP for these devices, and the distinctly differ-
ent body sites they are intended for: pelvic, H&N and breast
regions. Note that, currently, there is no clinical phased-array
applicator for breast hyperthermia; therefore, we propose a
benchmark applicator based on the HyperCollar design. The
proposed benchmark applicators contain a non-redundant
number of antennas for focused heating at depth [43] and
to accommodate different treatment planning algorithms.
Note that the applicators include simple dipole antennas to
enable easy implementation, regardless of the software used
for simulation.
The pelvic applicator (Figure 1 and Table 1) contains
twelve independent half-wavelength dipole antennas (total
length of 195mm with an 8mm gap/feed) operating at
120MHz and placed along the z-axis (caudal-cranial) in two
antenna rings separated by 19.5 cm. As in any hyperthermia
applicator, a water compartment (water bolus) is added to
cool the superficial tissues and couple energy from the
antennas toward the target [44]. For the benchmark applica-
tor, the water bolus covers the antenna array and has a
cylindrical shape with a diameter of 48.4 cm and a height of
59 cm. The H&N applicator consists of an array of twelve
half-wavelength dipole antennas (total length of 51mm with
an 8mm gap/feed) operating at 434MHz and placed along
the z-axis (caudal-cranial). The antennas are arranged over
three rings (separated by 4.5 cm) in a horse-shoe configur-
ation (arc ¼ 240) (Figure 2) to avoid placing antennas near
the nose, chin, ears and neck. The water bolus of our simpli-
fied setup has a cylindrical shape with a diameter of 34 cm
and a height of 16 cm. Note that the water bolus covers the
nose and eyes in this simplified setup, but in the clinical
applicators, it has a tailored shape to allow for breathing and
verbal feedback as well as preventing claustrophobia. The
breast applicator consists of an array of twelve half-wave-
length dipole antennas (total length of 51mm with an 8mm
gap/feed) operating at 434MHz and placed along the y-axis
(dorsal-ventral). The antennas are arranged over two rings
(separated by 29.5mm) and equidistantly spaced by 60
(Figure 3). This arrangement was inspired by a previous
adaptation of the HyperCollar applicator for testing hyper-
thermia feasibility in a model of a patient with breast cancer
[45]. The water bolus of our simplified setup has a cylindrical
shape with a diameter of 22 cm and a height of 16 cm. The
exact location of each antenna and patient center point is
provided in Appendix 3 (Table A1).
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2.3. Electromagnetic (EM) modeling benchmark
Several EM-simulation methods have been described in the
literature [46], either based on the differential or integral
form of Maxwell’s equations. The electromagnetic field distri-
bution is typically calculated using finite-difference time-
domain (FDTD) or finite-element (FEM) methods. To avoid
reflections of the electromagnetic waves at the boundaries
of the computational domain, several variations of absorbing
boundary conditions can be used, of which the perfectly
matched layer is recommended as the most effective [47,48].
For metallic surfaces, the use of a perfect electric conductor
boundary condition is recommended.
Another fundamental requirement for the numerical solu-
tion to be valid is mesh-independence. Time-domain meth-
ods like FDTD typically use a Cartesian grid, so the term grid
is often used instead of mesh. Meshes for electromagnetic
problems are often developed as a function of the wave-
length in tissue (kt). As a rule of thumb, the numerical
Figure 1. The benchmark pelvic applicator consists of 12 half-wavelength dipole antennas distributed over two rings. The benchmark patient models Clarice and
Will include tumors in the pelvic region. Note that the hyperthermia target volume (HTV) is the same as the gross tumor volume (GTV). The GTV is shown on the
right in 3 D together with just the skeleton for easier visualization of the target.
Figure 2. The benchmark H&N applicator consists of twelve half-wavelength dipole antennas distributed over three rings. The benchmark patient models Alex and
Murphy include a tumor in the nasopharynx and oropharynx regions (postoperative case), respectively. Only bones and tumors are shown for clarity, please refer
to Tables 2 and 3 for the complete list of tissues used in the model.
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problem can be initiated with a maximum mesh size of kt/4
(FDTD) and kt/8 (FEM), whereas an accurate solution will be
achieved by increasing the grid refinement to kt/15-kt/10
(FDTD) and kt/8- kt/6 (FEM) [49]. The resolution of the mesh
needs to be finer for regions with higher spatial gradients.
Nowadays, approaches exist that refine the resolution in
locations with high dielectric contrast, sharp/fine features, or
metallic objects, e.g., iterative, local-error-estimator-driven
adaptive mesh refinement or subgridding. Some manual
adjustments are recommended to improve mesh conver-
gence. For instance, accurate modeling of microstrip anten-
nas commonly used in applicators requires at least 2 mesh
cells within the substrate thickness, 2–4 mesh cells across a
strip, and 2 mesh lines in a radiating gap such as the dipoles
used in this paper [49]. The EM modeling of the benchmark
applicators was performed using the EM FDTD solver of
Sim4Life (v.5.2.0, Zurich MedTech, Zurich, Switzerland). The
antennas were excited with harmonic signals and simulated
for 20 periods to ensure steady state has been reached (for
implicit solvers, convergence-assessment based on residuum
reduction – by at least 8 orders of magnitude, and until no
significant changes are observed – is recommended instead).
Different grids were used to calculate the numerical solutions
for the pelvic, H&N and breast benchmark models. For the
pelvic model, a maximum grid size of 5mm was used in tis-
sue and a maximum grid size of 1.5mm was used in the
benchmark HT applicator. For the H&N and breast models, a
maximum grid size of 1.5mm was used in tissue and a
Figure 3. The benchmark breast applicator consists of 12 half-wavelength dipole antennas distributed over two rings. The benchmark patient models Venus and
Luna include a superficial and a deep-seated tumor, respectively.
Table 1. Description of the reference and correspondent simplified benchmark applicators.
Reference
applicator 1 Reference applicator 2 Benchmark applicator
Deep loco-regional HT in the pelvis Sigma-60 Sigma-Eye Pelvic applicator
60–120MHz 100MHz 120MHz
Cylindrical shape Eye shape Cylindrical shape
4 dipole pairs 12 dipole pairs 12 dipole antennas
1 antenna ring 3 antenna rings 2 antenna rings
Equidistantly spaced Equidistantly spaced Equidistantly spaced
Deep local HT in the H&N HyperCollar HyperCollar3D H&N applicator
434MHz 434MHz 434MHz
Cylindrical shape Horse-shoe shape Horse-shoe shape
12 patch antennas 20 patch antennas 12 dipole antennas
2 antenna rings 3 antenna rings 3 antenna rings
Equidistantly spaced Non-equidistant Non-equidistant
SuperficIal / deep local HT in the breast HyperCollar N/A Breast applicator
434MHz 434MHz
Cylindrical shape Cylindrical shape
12 patch antennas 12 dipole antennas
2 antenna rings 2 antenna rings
Equidistantly spaced Equidistantly spaced
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maximum grid size of 0.75mm was used in the benchmark
HT applicator. Then, the calculated field distributions from
irregular grid was intrapolated to a uniform grid of 5mm for
the pelvis models and 2.5mm for the breast and head and
neck models before optimizing the fields.
Convergence of the solution must be carefully ascer-
tained. A convergent solution is reached when the results of
interest do not change significantly with increasing mesh
refinement steps. Please note that convergence is not yet a
guarantee for solution correctness. For example, thermal
staircasing errors at boundaries are method-inherent and not
reduced by mesh refinement. For the electromagnetic com-
ponent of HTP, we recommend plotting the maximum SAR
or TC50 as a function of the number of mesh elements and
choosing the mesh such that the chosen parameter does not
vary by more than 1% between iterations, assuming a mesh
refinement factor of 1.3 per iteration. The parameter TC50
corresponds to the volume percentage of the HTV covered
by the 50% iso-SAR contour.
The EM energy is converted into heat through the lossy
nature of the tissue. The energy absorbed in the tissue can
be described by the SAR parameter, which corresponds to
the rate at which EM energy absorbed per unit mass of tis-
sue:
SAR ¼ r Ej j
2
2q
where r (S/m) is the electrical conductivity, q (kg/m3) is the
mass density, and jEj (V/m) is the magnitude of the local
electric field vector. The interaction of electromagnetic fields
with biological tissue is typically investigated using a macro-
scopic model involving the dielectric properties, i.e., relative
permittivity er and r. We suggest using the IT’IS Foundation
tissue property database v4.0 [28], which is the current de
facto standard for HTP and simulation studies. This database
is currently the most exhaustive collection of physical prop-
erties of human tissues. However, this database only contains
healthy tissues properties; so, for tumor dielectric properties,
we propose using the interpolated average from a variety of
tumor tissues (bladder, colon, kidney, liver, lung, lymph
nodes, mammary, spleen, and testes) measured within
50–900MHz [50]. To reduce the error from the interpolation,
we used a Lagrange 3rd degree interpolating polynomial
using the measured properties within 50–200MHz for
120MHz and 300–500MHz for 434MHz (Table 2).
2.4. Thermal modeling benchmark
The most commonly used thermal modeling for hyperther-





¼ r  krTð Þ  CbWb T  Tað Þ þ PLD
with Cp (J/kg/K) the specific heat capacity. The term r 
krTð Þ represents the heat conduction in tissue, with k (W/
m/K) the thermal conductivity. The second term on the
right-hand side models the blood perfusion, with Cb the
specific heat capacity of blood, Wb (kg/s/m
3) the volumetric
blood perfusion rate and Ta the local arterial temperature,
which is usually assumed to be the body core temperature
(37 C). The heat source term PLD (W/m3) corresponds to the
power absorbed in tissue from the external heating device.
Note that the original bioheat equation includes a metabolic
heat generation source term that is omitted in the proposed
benchmark studies since its effect is small relative to the
temperature increase, the dominant external heat source and
the blood perfusion heat sink terms. Furthermore, for prac-
tical reasons and since the therapeutic window coincides
with periods of relative temperature stability, we recommend
using a steady-state formulation for the bioheat equation,
where the time derivative on the left-hand side becomes
zero. Unless the treatment parameters are frequently
adapted (e.g., in a closed-loop control scenario), the transient
term can be neglected since the characteristic time of tem-
perature adaptation is short when compared to the treat-
ment duration. Optimization is also strongly facilitated by
using a steady-state formulation, and steady-state distribu-
tions can numerically be obtained more efficiently.
The largest sources of uncertainty in thermal simulations
are the blood perfusion values. When tissue temperature
increases, the local perfusion values are significantly
enhanced [53]. This enhancement depends on various fac-
tors, such as the local temperature elevation, the heating
duration, the tissue type, as well as other factors such as the
patient’s age and physical condition [54]. There are basically
two different options to model this enhanced perfusion dur-
ing hyperthermia: using a static thermal stress model [55] or
a temperature-dependent perfusion model [56]. All current,
clinically applied HTP software that relies on temperature
optimization use the static thermal stress model. Therefore,
to establish a clinical benchmark, we ignored the transient
variations of blood perfusion in our computations, and










Bone 434 13.07 0.094
120 14.85 0.067
Fat 434 11.59 0.082
120 12.45 0.069
Muscle 434 56.87 0.805
120 64.09 0.716
Lung 434 23.58 0.380
Cerebellum 55.11 1.048
Brain stem 55.11 1.048
Spinal cord 35.04 0.456
Eye (sclera) 57.37 1.004
Eye (lens) 37.29 0.379
Vitreous humor 69.00 1.534
Cartilage 45.14 0.598
Thyroid 61.33 0.886
Optical nerve 35.04 0.456
Tumor 434 57.20 0.884
120 66.40 0.753
Blood 434 63.83 1.361
120 74.03 1.244
Skin 434 46.06 0.702
Breast gland 434 49.15 0.747
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propose that all the computations be performed using static
blood perfusion under heat stress (Table 3) as reported in
[55]. Nevertheless, we do acknowledge that it can have a sig-
nificant impact on temperature predictions. The tumor ther-
mal properties were assumed to be the same as muscle,
except for perfusion. See references [7,9,52,57] for more
detail on thermal modeling.
The patient’s initial temperature was set to 37 C and
boundary conditions for the water bolus surface and external
air temperatures were fixed at 20 C for the pelvic (Clarice
and Will) and H&N (Alex and Murphy) models. For breast
models, a water bolus temperature of 40 C (Venus) and
30 C (Luna) was assumed. The clinically employed water
temperatures are in the range of 10–40 C, with low bolus
temperatures typically being used for deeper tumors [58]. A
convective boundary condition is more realistic than a fixed
temperature boundary condition, and should preferably be
used. Differences in boundary conditions primarily impact
1–2 cm of the adjacent tissue. Heat transfer coefficients in
the order of 6 and 40W/(m2 K) at the interface to the exter-
nal air and water bolus, respectively, are typically recom-
mended. However, the heat transfer coefficients are setup-
dependent (typically in the range of 2–40W/(m2 K); depend-
ing on forced vs. natural convection, velocity, and thermal
properties) and must be reported and justified. The heat
source terms calculated from EM simulations were interpo-
lated to a homogeneous grid and thereafter used for the
thermal simulations. For a mesh-independent solution, we
used and recommend analyzing the maximum temperature
(Tmax) and T50, so that they do not vary more than 0.05 C
after each consecutive mesh refinement iteration (assuming
a refinement factor 1.3 per refinement iteration). As pointed
out in Section 2.3, mesh convergence is a not a sufficient
condition for solution correctness regarding staircasing-
related thermal boundary effects.
2.5. Optimization benchmark
With HTP, phase and amplitude settings are optimized to real-
ize tumor heating above or close to a specified therapeutic
level [59–67]. The debate on whether SAR or temperature opti-
mization is the optimal choice in HTP is still open. Contrasting
arguments were proposed in literature [36,68,69] and our goal
is not to propose the optimal HTP approach but rather guide-
lines in how to implement and evaluate HTP platforms regard-
less of their basis. We encourage the community to compare
their novel HTP approaches with the most advanced
approaches in clinical use: the SAR-based optimization imple-
mented in VEDO [19] and the temperature-based optimization
implemented in Plan2Heat [8]. In this paper, we applied a SAR
optimization example for H&N, pelvic and breast benchmark
applicators using the patient models Murphy, Clarice and
Venus, respectively. The temperature optimization was applied
for the patient models Alex,Will and Luna.
2.5.1. SAR optimization
The proposed optimization strategy in this paper represents
the only example of SAR-based optimization routinely used
in the clinical practice. It is used for patients with both deep-
seated tumors in the pelvis and H&N, and is also proposed













Bone 1908 1313 0.32 0.33 10.0








Lung 394 3886 0.39 2.76 400.9
Cerebellum 1045 3653 0.51 14.08 770.0
Cerebrum 1045 3696 0.55 13.96 763.3
Brain stem 1046 3630 0.51 8.91 488.0
Spinal cord 1075 3630 0.51 3.02 160.3
Sclera 1032 4200 0.58 6.86 380.0
Lens 1076 3133 0.43 – –
Vitreous humor 1005 4047 0.59 – –
Cartilage 1100 3568 0.49 0.67 35.0
Thyroid 1050 3609 0.52 103.33 5624.3
Optical nerve 1075 3613 0.49 3.02 160.3
Tumor 1090 3421 0.49 1.80a 94.4a
Skin 1109 3391 0.37 2.06 106.4
10.59 547.0
Breast glandular 1091 3196 0.40 1.66 89.5
3.49a 189a
Internal air 1 10040b 0.03 – –
Blood 1050 3617 0.32 – –
aTissue properties under stress.
bThe specific heat capacity of air (1004 J/kg/K) was increased with a factor 10 to speed up thermal computations, which does not affect steady-state tempera-
tures. Alternatively, stability and matrix conditioning can be improved by excluding all air (including internal air) from the computational domain and applying
a convective boundary condition.
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here for patients with breast tumors. This approach aims at
maximizing the Target-Hotspot-Quotient (THQ), which is
defined as the ratio between the mean SAR in the HTV and
the average SAR in hot spots (HS), i.e., the 50ml of healthy
tissue that is exposed to the highest SAR [70]. The objective
function is then given by:
maximize THQ ¼ SARtarget
SARHS
 !
where the bar above SAR represents its average. The THQ
has been shown to correlate with simulated and later meas-
ured T50, an hence associates with HT outcome [71,72]. Note
that, in contrast to the relative definitions in literature, we
chose the absolute hotspot volume (50ml) as this enables
comparisons of the THQ’s values between different applica-
tions. Due to a non-convex nature of the optimization land-
scape, a global (Particle Swarm) optimizer is used to
optimize THQ [19]. Despite the non-null likelihood of select-
ing a suboptimal local optimum associated with non-convex
optimization approaches, stability can be maximized by
tumor-site/type-specific fine tuning of the search algorithm.
Further details on the THQ PSO are presented in [73].
2.5.2. Temperature optimization
The proposed approach for temperature optimization has
been introduced clinically about 15 years ago [74] and opti-
mizes an objective function h to aim for a specific goal tem-
perature range in the HTV. Several goal functions are
possible, but here we aim at a homogeneous temperature




T xð Þ< Tgoal
ðTgoal TðxÞÞ2 dx
where Tgoal was set to 43 C. Hard constraints of 44 C to
both tumor and normal tissue were applied to avoid thermal
injuries and a sequential quadratic programming (SQP)
method was used. In order to avoid a local optimum as a
final result, several optimizations with random initial phase-
amplitude settings should be performed. In our work, we
selected the best of 10 optimizations.
2.6. Evaluation benchmarks
For SAR-based quality indicators, we used THQ and target cover-
age (TC) on SAR field smoothed over 1 cm3 voxels (cfSAR) by
applying a 3D moving-average filter. TC parameters are defined
as the volume percentage of the HTV covered by the 25%
(TC25), 50% (TC50), and 75% (TC75) iso-cfSAR contour, with
cfSAR being normalized to the maximum cfSAR in the patient.
According to clinical practice, tumor coverage should be eval-
uated by the indexed temperatures T10, T50 and T90, which rep-
resent the temperatures achieved in at least 10, 50 and 90% of
the target volume, respectively. Both TCxx and Txx parameters
are used to quantify treatment quality based on measurements
and were shown to correlate with treatment outcome [75]. To
obtain relevant values quantifying simulation results, scaling of
the input power with strictly defined bounds is required. Hereto,
we propose to increase input power to achieve a maximum tem-
perature of 44 C, for both tumor and normal tissues.
2.7. HTP benchmark for focused ultrasound
Focused ultrasound (FUS) is used for thermal therapies in
the ablative and hyperthermic regimes as well as for revers-
ible blood-brain-barrier opening, noninvasive neurostimula-
tion, and targeted drug delivery. FUS generates deeply
localized, sharp, and potentially steerable foci at which
energy is deposited noninvasively. Heating frequently occurs
in combination with other physical effects, such as stable
and inertial cavitation, which can be desirable or not. While
targeting can be superior to that achieved using electromag-
netic applicators, it usually involves more complexities, e.g.,
due to the frequently larger number of treatment parame-
ters (e.g., amplitude and phase settings for hundreds of
source elements). The strengths and challenges are often
related to the fact that the waves attenuate little in tissue,
and acoustic wavelengths are short and of comparable mag-
nitude to small anatomical features and tissue heterogene-
ities. Also, strong, and sometimes, complex reflections at
bone interfaces or air often create insurmountable hurdles.
This paper is primarily focused on electromagnetic heat-
ing, but since FUS is becoming increasingly popular in hyper-
thermic oncology, this section will provide guidance, as well
as a benchmark, for FUS-based hyperthermia. As the clinical
reality demands treatment of large tumors, while a key
strength of FUS is its focality, a physical or electronic focus
scanning approach (or some novel alternative) is required.
Suitable solutions that do not result in surface overheating
are not yet generally available, and establishing a well-
defined benchmark that permits comparison of proposed
approaches is thus desirable. Such suitable applicators cap-
able of electronic steering are typically complex and can fea-
ture several hundreds of transducer elements [76]. Instead,
our proposed benchmark uses a simple spherical transducer
element without scanning for simplicity reasons, and focuses
on the patient model, acoustic and thermal properties. For
participants of the Grand Challenge, an objective could be to
devise a scanning strategy and/or corresponding phased-
array applicator that maximizes the thermal optimization
metric from Section 2.5.
2.7.1. Physical model and numerical solvers
A wide range of physical propagation models and numerical
solvers are being applied to the simulation of FUS. The most
complete description is based on stress-strain relationships
and involve deformation vectors, tensors, and complex
material models (e.g., fiber-enforced, non-linear materials).
However, such simulations quickly become too resource-
intensive, leading to necessary simplifications. Pressure waves
are frequently simulated, rather than displacement waves, at
the cost of not capturing shear-wave effects. The most com-
mon formulations are the linear acoustic pressure wave
equation (LAPWE):










where p is the pressure, c is the speed of sound and ~a
is related (and sometimes equated) to attenuation. The
non-linear extension of LAPWE, the Westervelt-Lighthill equa-
tion (WLE, [77]), accounts for dispersive properties and fre-
quency mixing (but is typically not appropriate for the large
















where c0 is the equilibrium speed of sound, d is the diffusiv-
ity, b is the non-linearity coefficient, and q0 is the equilibrium
density of the fluid.
For setups in which one propagation direction dominates,
paraxial approximations are commonly employed. In hyper-
thermic FUS applications, the linear acoustic pressure wave
solver (LAPWE) is recommended and full-wave 3D solvers
should be used. The most frequent numerical solvers use
(hybrid) angular spectrum approaches [78], finite element
and finite differences time-domain methods [79,80], and
pseudospectral methods [81]. These methods come with
their own numerical error sources related to spatial and tem-
poral discretization, time-integration schemes, and conver-
gence. Performing refinement and convergence analyses
when applying a method to a new context-of-use is there-
fore strongly recommended. For a detailed discussion of
acoustic solver verification and validation, see reference [82].
2.7.2. Material properties and heterogeneity
Reported values for acoustic tissue properties vary strongly.
It is recommended to use reference [28] for a curated, litera-
ture-based, versioned (for reproducibility) and regularly
updated collection, which also reports recommended values
and information about associated uncertainty. Particularly for
transcranial focused ultrasound (tcFUS) the highly heteroge-
neous structure of skull and bone cannot be neglected as it
leads to scattering, beam and focus distortion and aberra-
tion, absorption and heating, shear waves, and standing
waves. It can be necessary to use personalized information,
e.g., from CT scans, to produce patient-specific property
maps for the simulations [83]. For tcFUS, heterogeneity in tis-
sues must be considered.
2.7.3. Energy deposition, induced heating, tissue damage
Acoustic absorption leads to induced tissue heating. The
power deposition can be computed through the formula
ap2/qc, with a being the absorption coefficient. While not
commonly considered, it can be important to distinguish
between attenuation and absorption, as effective attenuation
encompasses both absorption and scattering, but is com-
monly referred to as absorption. For transient (e.g., pulsed)
exposures, whether transient simulation of the exposure is
required or temporal averaging is acceptable depends on
the relative magnitudes of the characteristic pulsation/modu-
lation and the characteristic heating time scales. Modeling of
acoustic and electromagnetic heating is typically performed
in a similar manner (i.e., using the Pennes bioheat Equation
[51]), unless the acoustic heating involves temperatures at
which vascular shutdown and coagulation becomes import-
ant, where similar methods are applied as for RF ablation
modeling [84]. Again, it can be important to specifically
account for large vasculature in the vicinity of the heated
domain. Common tissue damage metrics include the
Arrhenius tissue damage model, thermal dose models (such
as CEM43, [85]), and thermal iso-levels (typically chosen at
50–55 C). In what concerns the water bolus, frequently used
for impedance matching and surface cooling, similar consid-
erations as for electromagnetic hyperthermia applica-
tors apply.
2.7.4. Source modeling
There is no generally accepted way in how acoustic trans-
ducers are modeled. Depending on the employed physical
model, either given pressures or displacements or velocities
are applied, which are not equivalent and complicate com-
parison. Furthermore, it can be important to model the
internal structure of transducers [86], which often contain
impedance matching and lens elements and can be affected
by mechanical factors, such as fixation and friction.
2.7.5. Targeting
Many approaches for acoustic targeting, steering, and aberra-
tion compensation have been proposed [87]. When larger
regions are to be heated, e.g., in the context of hyperthermic
oncology, spatial scanning is typically required, and the heat-
ing performance (efficiency, localization, homogeneity)
strongly depends on the scanning strategy.
2.7.6. Benchmark
The benchmark for the ESHO Grand Challenge shall consist
of the patient model Venus. The provided benchmark makes
no use of physical or electronic focus scanning and instead
predicts the acoustic exposure and induced heating from a
spherical transducer (geometric radius: 10 cm, aperture angle:
73.7 deg (10 cm), frequency: 1.6MHz, pressure at the source:
16 kPa) placed vertically below the tumor center (assuming
lying position), at a distance equal to the transducer curva-
ture radius. Thermal simulations are performed according to
Section 2.4 and the acoustic properties from [28] are used
(tumor is treated as glandular breast tissue [88]). The shared
reference solution has been generated using an FDTD acous-
tic solver (Sim4Life v5.2.2), a grid resolution of at least a
tenth of a wavelength throughout (the provided reference
solution used a grid resolution around 0.09mm and 2.6
Billion voxels), perfectly matched layer boundary conditions,
Dirichlet pressure sources, and a run-time of 200 periods.
Heating for a duration of 2700s was simulated using an
FDTD thermal solver (Sim4Life v5.2.2) and a grid with 30.6
Million voxels was used with a maximum grid-step of
1.9mm. The acoustic and thermal results can be seen in
Figure 4, which illustrate how the actual focus location
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deviates from the geometric focus and how its shape is dis-
torted, which also affects the induced heating.
3. Results
Figure 4 (top row) shows the optimized SAR and correspond-
ing temperature distributions for the Murphy, Clarice and
Venus patient models chosen for the SAR optimization
benchmark. Similarly, Figure 4 (bottom row) shows the opti-
mized temperature and corresponding SAR distributions for
the Alex, Will and Luna patient models, chosen for the tem-
perature optimization benchmark. The quality indicators for
SAR (THQ, TCxx) and temperature (Txx) are reported for all
cases in Table 4, irrespective of the optimization method
Figure 4. THQ (Murphy, Clarice, Venus) or T50 (Alex, Will, Luna) optimized SAR and temperature distributions for the benchmark applicators displayed on top of
the CT images with the target region indicated by the green contour. Axial and sagittal cross-sections are given for Murphy and Alex and axial and coronal cross-
sections for Clarice, Venus, Will and Luna. Note that the CT slice of Claris and Will also includes the slings (lines, dots) on which patients are scanned and treated.
The FUS results for Venus show the SAR and temperature distributions for a single pressure focus, i.e., without focus scanning.
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used. Note that direct comparison of temperature and SAR
optimization were not performed since literature shows that
this comparison is strongly affected by dielectric and thermal
tissue properties as well as their uncertainties [36]. By provid-
ing both options, we aim to accommodate benchmarking
options for those working on SAR optimization and those
working on temperature optimization.
SAR optimization with benchmark applicators was able to
pass the inclusion criteria (TC25> 75%) set in VEDO [19] for
H&N, pelvic and breast cancer patient models and all models
also had a satisfactory T50 (above 40 C) as indicated in
Table 4. Note that the Murphy model incorporates an easier
to heat target location, however the lack of a highly absorb-
ing solid tumor mass (high electrical conductivity) resulted in
low TC50 values. A high THQ and target coverage was found
for Clarice, representing an average hyperthermia treatment
scenario. As expected, temperature optimization resulted in
higher T50, even though both cases had unconventional
tumor shapes.
Figure 4 and Table 4 also illustrates the results of the
acoustic exposure benchmark, in terms of pressure and
induced heating. It is apparent that - despite aligning the
geometric focus of the applicator with the center of the
tumor - the heterogeneity of the acoustic properties results
in a shifted and distorted focus. It is also evident that phys-
ical or electronic scanning of the focus is required to prop-
erly ensure tumor coverage.
4. Discussion
4.1. Clinical model selection
Patients models from the EVPR database and two new breast
models were chosen to represent difficult to heat scenarios
within their respective clinically treated patient populations.
Note that the current clinical practice in hyperthermia breast
cancer focuses on recurrent disease, requiring the use of
superficial applicators instead of the phased array devices as
analyzed in this paper. The inclusion of models with tumors
in the intact breast should be considered as a first step
toward clinical phased-array device development, rather than
building on an ongoing routine clinical application like in
H&N and pelvic hyperthermia.
SAR and temperature optimization led to distinct results
in terms of temperature quality indicators in the models,
which can be explained by the fact that, during SAR opti-
mization, the THQ is the objective function to maximize and
not the temperature (see also section 4.4). Note that we did
not investigate the dependence on tissue properties uncer-
tainties, which has been reported to strongly affect differen-
ces between quality metrics for SAR and temperature
optimization [36]. Our results also show that the proposed
benchmark applicators provide sufficient heating and
degrees of freedom for field shaping and, hence, a solid
ground to compare novel optimizers and hyperther-
mia devices.
4.2. Tumor properties
Tumors show an even more considerable inter-subject vari-
ability than normal tissues, such that any patient-specific
information about tumor properties is valuable. It should
also be noted that tumors are frequently highly heteroge-
neous (e.g., well-perfused rim, but necrotic core) and may
not be represented sufficiently by assigning homogeneous
tissue properties to segmented regions. The impact of this
approximation, however, is to date unknown. The IT’IS tissue
properties database only lists healthy tissue properties. For
tumor dielectric properties, we propose using the average of
bladder, colon, kidney, liver, lung, lymph nodes, mammary,
spleen, and testes tumors measured within 50–900MHz [50].
The dielectric properties variability between these tissues
was ±25%, except for relative permittivity at 50MHz that var-
ied within 24% to þ39% from the average. As many other
tissue properties retrieved from literature, these properties
were measured at room temperature (23–25 C) 1–2 h after
being excised from the human body. The water content is
very likely decreased for ex vivo samples, which decreases
the measured values. On the other hand, the samples were
measured at a significantly lower temperature than normo-
thermia which also tends to lower dielectric properties. We
accept these limitations since, when performing simulations
with lower dielectric properties, the hyperthermia tempera-
ture increase is also expected to be lower, meaning that we
are analyzing dielectric tissue properties for a likely worst-
case scenario. Note that healthy tissue properties also pre-
sent significant variability. The IT’IS tissue properties database
lists the measured ranges, standard devitation and number
of samples, facilitating tissue-specific sensitivity analyses.
4.3. Optimization goals
In this work, the goal temperature in the target was set to
43 C, since the widely accepted optimal treatment is when
tumor temperatures are maintained as close as possible to
43 C for 60min [89]. However, in the clinical setting, the
goal temperature of 43 C is often challenging to achieve
with locoregional hyperthermia equipment. For all thermal
simulations, hard constraints of 44 C to both tumor and nor-
mal tissue were applied to avoid thermal toxicity. We used
homogeneous tumor properties, but tumors can be very het-
erogeneous with poorly perfused or even necrotic regions.
Nevertheless, thermal toxicity at the tumor location and its
Table 4. Treatment planning results achieved using the benchmark applica-
tors and optimized based on SAR (THQ) with VEDO software or based on tem-

















THQ – SAR Murphy 0.63 85 31 0 39.1 40.7 41.8
THQ – SAR Clarice 0.65 97 58 0 39.4 41.0 41.9
THQ – SAR Venus 1.10 100 78 7 39.4 40.9 42.6
FUS Venus 1.28 0 0 0 35.6 37.8 39.9
Goal 43 C – T Alex 0.23 0 0 0 40.0 41.5 42.9
Goal 43 C – T Will 0.53 91 13 0 41.3 42.6 43.6
Goal 43 C – T Luna 0.83 100 86 11 41.1 42.2 43.2
Note that a T50 of more than 40 C is generally considered sufficient for treat-
ment, but that treatment effect is expected to increase when temperatures
are closer to 43 C [6].
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surroundings should be avoided since ill-defined thermal
ablation could reduce the radiosensitization effect of hyper-
thermia [90]. In clinical practice, treatment guidance is usu-
ally performed using temperature probes inserted at or near
the tumor location, as well as patient feedback from heating
discomfort or pain from hot spots. To aim for sufficiently
high tumor temperatures, the applicator power is usually
increased until treatment-limiting hot spots (or excessive
measured tumor temperatures) occur. The threshold tem-
perature for hot spot-related pain complaints has been
reported to be near 45 C [91], but clinical experience shows
that pain is sometimes reported by the patient at lower tem-
peratures. Hence, the maximum normal tissue temperature
was set to 44 C in the proposed HTP guidelines. The slightly
lower constraint was mainly chosen because of the uncer-
tainties in (thermal) modeling caused by uncertainties in tis-
sue properties and perfusion, as well as impaired perfusion
at locations where surgery was applied.
4.4. Clinical relevance of SAR/T optimization factors
Clinically relevant SAR indicators for evaluation and optimiza-
tion of treatment plans should be predictive for temperature
and thus show a good correlation with temperature. Both
THQ and TC (TC50 and TC25) are predictive SAR indicators,
as demonstrated in planning studies for locoregional and
H&N hyperthermia [70,71]. In clinical superficial hyperthermia,
TC25 was also shown a prognostic factor for local con-
trol [92,93].
For thermal modeling, plan evaluation is usually per-
formed based on the indexed temperatures T10, T50, and
T90, which are commonly used clinical indicators to evaluate
treatment quality. Especially T90 is correlated with clinical
outcome [94,95], and is therefore also often used as the
objective function to maximize during temperature-based
optimization, as an alternative for the goal temperature of
43 C [13,36].
4.5. Sar vs T optimization
Both the SAR-based and temperature-based optimization
approaches used in this study aim to maximize tumor heat-
ing, albeit using a different approach. The SAR-based opti-
mization optimizes the THQ, i.e., the energy deposition in
the tumor vs. local exposure peaks, but does not take into
account significant thermal effects such as bolus cooling,
thermal diffusion (mimicked by SAR smoothing), and blood
perfusion, while the temperature-based optimization directly
optimizes the target temperature distribution with con-
straints to normal tissue temperatures. Thus, the employed
temperature optimization metric puts a higher weight on
average behavior, only giving a small weight to volumetric-
ally small hot spots, as long as they remain below the
threshold. The considered SAR optimization metric focuses
on hot spot suppression, compromising on achievable tumor
heating. This difference explains why temperature-based
optimization typically yields a lower THQ than SAR-based
optimization, while SAR-based optimization frequently results
in lower tumor temperatures compared to direct tempera-
ture-based optimization (Table 4). This difference in approach
makes a direct comparison of optimization results difficult.
Thus, this paper does not intend to advise a specific opti-
mization approach. However, one should be aware that these
differences can substantially affect optimization results in sys-
tem design studies [96]. For example, a study by Seebass
et al. showed that using SAR-based optimization of a single-
ring antenna array set up with 12 independent dipoles was
optimal for locoregional heating, while using temperature-
based optimization, a three-ring system with four dipole
pairs showed the best performance [96].
Despite the differences in the optimization approach, as
described above, both SAR- and temperature-based optimi-
zations have been successfully applied in clinical hyperther-
mia for many years [19,74]. A SAR-based optimization used
clinically and suggested in this paper is a particle swarm
optimization (PSO): a metaheuristic method that can effect-
ively search very large spaces of candidate solutions. The
clinical temperature-based optimization, as suggested in this
paper, uses a sequential quadratic programming (SQP)
method and selects the best result out of several optimiza-
tions started with random initial amplitude-phase settings.
Although both PSO and SQP cannot guarantee that a math-
ematically optimal solution is obtained, results are generally
suitable for clinical use.
Initially, SAR-based methods were more popular because
they are computationally much cheaper. Temperature-based
methods are more time-consuming because of the explicit
constraints to normal tissue temperatures to be accounted
for. However, since computational power has increased sig-
nificantly in recent years, and efficient superposition meth-
ods are available for temperature calculations [60,97,98],
thermal optimization has become increasingly popular and
can even be performed online during treatment.
Uncertainties in dielectric and thermal tissue properties still
limit the quantitative accuracy of both SAR and temperature-
based pretreatment planning optimization [36,99–102].
Therefore, adjustments during treatment in response to hot
spots remain necessary, and both predicted changes in SAR
and temperature correlate with measured temperature
changes after phase-amplitude steering [100,103].
4.6. Bioheat and blood perfusion modeling
The bioheat equation has become the de facto standard in
hyperthermia thermal simulations [9,21,51]. In this mathemat-
ical model of heat transfer in living tissues, blood perfusion
is assumed to be non-directional and heat disappears from
the tissue via a heat-sink term. The validity of this equation
was demonstrated for heating a large region in tissue with
healthy microvasculature and blood flowing through vessels
with isotropically distributed orientations. However, this
assumption can result in inaccurate temperature predictions
in highly vascularized body parts such as neck or prostate
[104,105]. To take into account of the non-continuum nature
of perfusion and non-equilibrium effects, several different
thermal models were proposed [106–111]. However, these
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models require integrating discrete vasculature into the
modeling, which is a time-consuming process for both
patient and pretreatment planning [104,112]. Approaches,
such as the one from [99], which considers the spatial vari-
ability of the arterial blood temperature and its convection
field, depend on a large number of additional properties and
even property fields. For this approach, little information
from HT is available and personalization to a specific patient
is currently unfeasible. Despite the limitations of the PBHE,
we still recommend it for clinical applications because it
leads to reasonable estimates in a timely manner within the
known uncertainty of tissue properties [9].
To make the bioheat model more relevant for hyperther-
mia therapy, we also recommend the use of blood perfusion
properties under stress. The bioheat formulation proposed is
static and does not account for the transient effects of perfu-
sion as a function of temperature. Several groups have dem-
onstrated changes in tissue blood perfusion of over ten
times during heating in the 40–44 C range [53,113,114].
Blood perfusion transiently increases during mild heating,
but with higher temperatures (43–45 C depending on tis-
sue), vascular damage will occur, leading to a rapid decrease
in blood perfusion [53]. Accounting for this non-linear time-
and temperature-dependent effect on blood perfusion would
be computationally challenging and the available (human)
experimental data basis is weak, leading to significant
uncertainties.
The proposed static thermal stress model assumes an
enhancement factor per tissue type, for average hyperther-
mic temperatures. This assumption still yields a constant per-
fusion thus facilitating fast simulations. There are no widely
accepted standard models for transient thermoregulation in
humans, at least not on the tissue level – see [115] for
whole-body thermoregulation standardization. Therefore, in
this guidance document, we omit temperature dependence
in view of simplicity. As physiological understanding, imaging
technologies for personalization, and computational model-
ing technologies progress, it would be desirable to improve
the modeling of perfusion/vasculature, thermoregulation,
and transient effects, and to further adapt simulations to
individual patients. Note that all remaining tissue properties
(e.g., electrical conductivity, density, and heat capacity) do
not vary significantly within the hyperthermia range
(40–44 C), but the temperature effects should be taken into
account in all tissue properties for ablation procedures [7].
4.7. Model verification and validation
Proper model verification (ensuring correct model implemen-
tation) and validation (ensuring that the model captures the
relevant features of reality) are crucial for establishing confi-
dence in the reliability of treatment modeling in terms of
treatment risk and effectivity prediction. Both verification
and validation are critical for any regulatory submission sup-
ported by evidence from computational modeling or involv-
ing computational modeling in the treatment planning,
optimization, or application. Regulatory acceptance is a
requirement for HTP to be widely applied outside of research
conditions and for modeling-supported applicator develop-
ment. The corresponding Food and Drug Administration
(FDA) guidance document [116] and the ASME V&V 40 stand-
ard [117] provide valuable guidance on establishing, demon-
strating and reporting the level of rigor needed for
computational modeling used in support of a regulatory sub-
mission of any medical device or software intended to treat
patients, such as HTP platforms.
The benchmarks presented in this paper can be valuable
for the purpose of hyperthermia treatment modeling verifica-
tion (i.e., ascertaining that the model implementation is as
intended). However, validation (i.e., ensuring that the
intended model reproduces the real-world behavior of the
relevant quantities-of-interest with sufficient accuracy) will
typically require experimental data to ensure agreement with
reality, which is usually obtained in the thermal medicine
field through phantom testing (see [118] for EM and [82] for
acoustic modeling) or in vivo test data. The latter is strongly
preferable for thermal validation, in view of the critical
impact of perfusion [10,39]. Providing guidelines to experi-
mental validation of the computational models is outside the
scope of this guideline paper, but we encourage the reader
to read references [26,27,119–121]. The key aspect to keep in
mind is that the computational methods used in hyperther-
mia applications will support decisions that will influence the
safety and health of patients. Both standards and guideline
documents, such as this paper, are key elements for the
development of safe and effective hyperthermia technology.
For a detailed discussion on verification, validation, uncer-
tainty quantification and quality assurance for computational
anatomical models and related applications, see reference
[122]. Thus, the here elaborated benchmarks, are intended
for implementation verification of different numerical
approaches used for HTP and performance comparison of
different hyperthermia applicators benchmarks; which is in
line with the according to Merriam-Webster’s definition
“benchmark: a standardized problem or test that serves as a
basis for evaluation or comparison (as of computer system
performance)”. To be clear, – these benchmarks have not
been experimentally validated to ascertain that they faithfully
reproduce the biophysical reality.
5. Conclusions and outlook
In this paper, we present new hyperthermia applicator
benchmarks, anatomical models and simulation parameters
to stimulate standardization in simulation studies of hyper-
thermia technology. The focus was on current clinical hyper-
thermia applications in the pelvic region, H&N, and breast. In
summary, the presented benchmarks and guidance in this
paper aimed at:
 Standardization: We foresee that advancing standardiza-
tion will improve treatment quality and facilitate the com-
parison of different hyperthermia approaches.
 Benchmarks: Providing benchmarks not only serves to
facilitate such comparison, but will also drive
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technological advances as well as being crucial for code-
verification and quality assurance.
 ESHO Grand Challenge 2021: The benchmarks are of dir-
ect relevance to the forthcoming ESHO Grand Challenge
2021, as they can serve as objective metrics and permit
to objectively quantify claims across different
submissions.
 Guidance: The methods and parameters used in hyper-
thermia treatment modeling vary greatly across literature
and practice, and the rationale for choices is not always
apparent. This paper also aims to provide guidance and
justification in that respect. It also aims to clarify the add-
itional research required to further progress in
HTP technology.
It is our hope that this publication is valuable to practi-
tioners and researchers in the field of hyperthermic oncol-
ogy, while providing input for more comprehensive future
standardization of computational-based platforms for use in
hyperthermia cancer therapy.
Emerging tumor sites, where HT application has the
potential to significantly improve the current care, such as
pancreas or brain tumors, were left for future challenges. In
addition, FUS-based hyperthermia is only briefly discussed,
and other heating technologies, such as nanoparticles or
magnetic seeds are not considered in this paper.
Note
1. Details on the ESHO grand challenge on HTP will be provided at https://
www.esho.info/
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Appendix 1. Summary of the proposed guidelines
for computational modeling in hyperthermia
This appendix establishes the recommended minimum level for the
computational modeling of hyperthermia therapy.
Patient models
 Use of detailed patient models with the relevant anatomical reso-
lution and tissues (including tumor tissue) is strongly recommended.
RF/MW simulations
A specific recommendation on how to carry out EM calculations in HTP
as discussed in Section 2.3:
 For metallic regions, the use of a perfect electric conductor (PEC)
material is advised.
 From a numerics perspective, the grid resolution should be initiated
at kt/15-kt/10 (FDTD) or kt/8- kt/6 (FEM) and a grid refinement con-
vergence analysis should be performed.
 In addition, to ascertain proper resolution of the anatomical hetero-
geneity and structure, it is heuristically recommended that the max-
imum grid step for applications similar to the presented benchmarks
be chosen as follows:
 for the pelvic region and regions with similar dimensions, using
applicators heating patterns similar to the provided benchmarks:
a maximum step size of 5mm in tissue and a maximum grid
step of 1.5mm in the HT applicator.
 for the H&N, breast models and regions with similar dimension,
using applicators heating patterns similar to the provided
benchmarks: a maximum grid step of 1.5mm in tissue and a
maximum grid step of 0.75mm in the applicator.
 The grid convergence of the solution should be ascertained by plot-
ting the maximum SAR or TC50 as a function of the number of
mesh elements. Other metrics may be used, if well justified.
 The dielectric properties of healthy tissues and tumor should be cal-
culated according [28] and [50], respectively.
 Should the results be resampled, a minimal resolution of 5mm for
the pelvic models (or similar) and 2.5mm for the breast and H&N
models (or similar) is recommended.
 For time domain simulations, the antennas are typically excited with
harmonic signals and simulated for at least 20 periods (dependent
on the domain-size/wavelength ratio and the Q-factor of the applica-
tor). Convergence analysis (i.e., achievement of periodic results) is
recommended.
 For time-domain methods, perfectly matched layer (PML) boundary
conditions are recommended.
 For implicit solvers, convergence assessment based on residuum
reduction is recommended (at least by 8 orders of magnitude, until
no significant changes are observed).
US simulations:
A specific recommendation on how to carry out FUS calculations in HTP
as discussed in Section 2.7:
 LAPWE is recommended and full-wave 3D solvers should be used
 For FDTD simulations, kt/12 resolution is recommended, but should
be accompanied a grid convergence analyses
 For FDTD, simulations, PML boundary conditions and Dirichlet pres-
sure sources are suggested.
 For transcranial FUS the highly heterogeneous structure of skull and bone
cannot be neglected and property maps (e.g., from CT) should be used.
 The acoustic tissue properties of reference [28] should be used. For
breast tumor, glandular breast tissue properties should be used [88].
 In the context of HT, spatial scanning is necessary as a result of the
high FUS focality to achieve an adequate temperature distributions
Thermal simulations
Unless the hypthermia therapy is applied in a dynamic fashion (e.g.,
time-modulated), thermal simulations shall be performed according to
Section 2.4, i.e.,
 Apply a steady-state formulation of the Pennes’ bioheat equation for
temperature optimization
 Computations are performed using static blood perfusion under heat
stress (Table 3).
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 We recommend that solver convergence is ascertained, as the
required degree of residuum reduction depends on the heating
focality and initial condition (e.g., 37C).
 Dirichlet or Convective boundary conditions should be used for the
water bolus interface (the reference temperature will typically be in
the range 10–40 C, depending on the specific treatment protocol),
as well as interfaces to internal and external air, and major blood
vessels. For Convective boundary conditions, the convective coeffi-
cients must be provided and justified. They are typically in the range
of 2–40 W/m2/K (depending on forced vs. natural convection, vel-
ocity, and thermal properties).
 For the calculation of the quality metrics and as general recommen-
dation (unless the treatment protocol demands otherwise), the input
power is scaled such that both tumor and normal tissue tempera-
tures do not exceed 44 C. In case of brain and eyes, the tissue tem-
peratures should not exceed 42 C.
Optimization and quality metrics
The optimization metrics from Section 2.5 have been clinically used as
they were shown to correlate with simulated and measured T50, as well
as treatment outcome. Therefore, we recommend applying and/or
reporting on the metrics stated below.
 For SAR-based quality indicators, both Target-Hotspot-Quotient
(THQ) and target coverage (TC) metrics on the smoothed SAR field
(1 cm3 moving-average filter; cfSAR) are desirable. The cfSAR is nor-
malized to the maximum cfSAR in the patient.
 Tumor coverage is evaluated by the indexed iso-temperatures T10,
T50 and T90 when scaling the exposure to a maximal temperature
of 44 C, for both tumor and normal tissues.
 In order to increase the chance of identifying the global optimum,
performing several optimization runs with random initial phase-amp-
litude settings is recommended.
 Reporting on the duration of the optimization producedures and the
employed computational hardware is encouraged.
Appendix 2. ESHO 2021 grand challenge on
hyperthermia computational modeling
The purpose of the ESHO Grand challenge is to drive and facilitate the
standardized evaluation of new hyperthermia applicator and treatment
optimization techniques. The simulated performance of novel
technologies will be compared with benchmark applicators and anatom-
ical models. Detailed instructions of the challenge are published at
https://www.esho.info/ESHOGrandChallenge.
The available datasets contain segmented patient voxel models, elec-
tric field distribution generated by the benchmark applicators, and amp-
litude/phase values of the optimized antenna steering parameters. To
request the datasets, an email with the subject ‘ESHO-GC-setup’ should
be sent to ESHOgrandchallenge2021@conventus.de.
Hyperthermia treatment planning (HTP) approaches
We encourage to use all available benchmarks of anatomical models
and applicators. The applicators shall remain unaltered. The dielectric
properties of healthy tissues and tumor must be assigned according to
[28] and [51], respectively. Thermal modeling must be carried out as
described in Section 2.4.
Novel applicator developments
We encourage to apply proposed novel applicators to two different pro-
vided anatomies. If the investigated frequencies deviate from those in
the benchmarks, the dielectric properties of healthy tissues and tumor
must be calculated according [28] and [51], respectively, and reported.
Note that new applicator proposals may be accompanied with new opti-
mization approaches.
US HT
The provided acoustic benchmark for the ESHO Grand Challenge con-
sists of the patient models Venus and simulates the acoustic exposure
and induced heating from a spherical transducer (see Section 2.7 regard-
ing placement and geometry). Thermal simulations shall be performed
according to Section 2.4 and the acoustic properties from [28] must be
used. The simulation methods shall support full-wave 3D modeling (e.g.,
FDTD or pseudo-spectral method). For FDTD solvers, PML boundary con-
ditions should be employed and it must be ascertained that the number
of layers prevents significant reflections at the domain boundary. The
thermal optimization metrics from Section 2.5 apply for treatment
optimization.
In view of the high focality of FUS, – which is a strength for target-
ing, but also poses a challenge when treating larger tumors, we encour-
age participants to investigate/devise scanning strategies and/or
corresponding phased-array applicators that permit to maximize the
thermal optimization metrics from Section 2.5.
Appendix 3. Patient – device positioning settings
Table A1. Center point of the patient models, water bolus and antennas.
Alex Murphy Will Clarice Venus Luna
Patient (1.89, 1.68, 7.62) (4.89, 16.58, 7.98) (4.88, 116.21, 45) (8.3, 275.55, 473.5) (3.3, 44.8, 184.2) 2.6, 89.6, 163.4
Water Bolus ( 0, 0, 58) (0, 16, 5) (0, 49, 0) (0, 340, 506) (95, 90, 188) (96, 165, 170)
Antenna 1 (120, 102,59.5) (120, 100, 8.5) (295, 49, 98) (295, 340, 604) (120.9, 60, 91.4) 0.6, 135, 195.9
Antenna 2 (134, 78, 104.5) (134, 76, 53.5) (147.50, 304.48, 98) (147.5, 84.52, 604) 191.6, 60, 162.1 70.1, 135, 266.6
Antenna 3 (144, 52, 14.5) (144, 50, 36.5) (147.50, 304.48, 98) (147.5, 84.52, 604) 165.7, 60, 258.7 166.7, 135, 240.7
Antenna 4 (148, 24, 59.5) (148, 22, 8.5) (295, 49, 98) (295, 340, 604) 69.1, 60, 284.6 192.6, 135, 144.1
Antenna 5 (147, 3, 104.5) (147, 5, 53.5) (147.5, 206.48, 98) (147.5, 595.48, 604) 1.6, 60, 213.9 121.9, 135, 73.4
Antenna 6 (140, 30, 14.5) (140, 32, 36.5) (147.5, 206.48, 98) (147.5, 595.48, 604) 24.3, 60, 117.3 25.3, 135, 99.3
Antenna 7 (120, 102, 59.5) (120, 100, 8.5) (255.48, 196.5, 98) (255.48, 192.5, 409) 69.1, 89.5, 91.4 0.6, 164.5, 144.1
Antenna 8 (134, 78, 104.5) (134, 76, 53.5) (0, 344, 98) (0, 45, 409) 165.7, 89.5, 117.3 25.3, 164.5, 240.7
Antenna 9 (144, 52, 14.5) (144, 50, 36.5) (255.48, 196.5, 98) (255.48, 192.5, 409) 191.6, 89.5, 213.9 121.9, 164.5, 266.6
Antenna 10 (148, 24, 59.5) (148, 22, 8.5) (255.48, 98.5, 98) (255.48, 487.5, 409) 120.9, 89.5, 284.6 192.6, 164.5, 195.9
Antenna 11 (147, 3, 104.5) (147, 5, 53.5) (0, 246, 98) (0, 635, 409) 24.3, 89.5, 258.7 166.7, 164.5, 99.3
Antenna 12 (140, 30, 14.5) (140, 32, 36.5) (255.48, 98.5, 98) (255.48, 487.5, 409) 1.6, 89.5, 162.1 70.1, 164.5, 73.4
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